The Tesamorelin + Ipamorelin blend combines two growth-hormone-axis research peptides in a single vial: Tesamorelin, a stabilized GHRH-receptor analog, and Ipamorelin, a selective ghrelin/growth-hormone-secretagogue-receptor agonist. For research groups studying complementary secretagogue pathways, the blend enables side-by-side investigation of GHRH- and ghrelin-receptor signaling in the same preparation. Puritide Research supplies this blend as a high-purity, research-use-only material, prepared for in vitro and animal-model work and backed by third-party-verified certificates of analysis so your data rests on consistent, documented quality.
Available Sizes
- ›Tesamorelin + Ipamorelin Blend 17mg (11+6) Vial
Product Specifications
- Application
- Combined GHRH-receptor and ghrelin/GHS-receptor secretagogue research
- Appearance
- Solid, white lyophilized powder in a sealed glass vial
- Chemical Formula
- Blend, Tesamorelin C221H366N72O67S; Ipamorelin C38H49N9O5
- CAS Number
- Blend, Tesamorelin 218949-48-5; Ipamorelin 170851-70-4
- Molecular Weight
- Blend, Tesamorelin ~5135.87 g/mol; Ipamorelin ~711.86 g/mol
- Synonyms
- Tesamorelin + Ipamorelin, TH9507 + Ipamorelin blend, GHRH analog / GHS-R agonist blend
- Storage
- Store at ≤25°C, sealed, away from heat, light, and moisture. For extended storage, keep lyophilized and refrigerated or frozen.
What Is the Tesamorelin + Ipamorelin Blend?
This blend is a co-formulated research preparation containing two distinct peptides: Tesamorelin, a synthetic 44-residue analog of growth hormone-releasing hormone (GHRH) stabilized by an N-terminal trans-3-hexenoyl modification, and Ipamorelin, a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective agonist of the ghrelin / growth hormone secretagogue receptor (GHS-R). The 17 mg total reflects an 11 mg + 6 mg ratio of the two components.
In laboratory settings, the blend is studied to investigate two complementary secretagogue mechanisms in a single system: GHRH-receptor agonism (Tesamorelin) and ghrelin-receptor agonism (Ipamorelin). These pathways converge on somatotroph growth-hormone signaling through different receptors, making the blend a useful tool for studying pathway complementarity.
Present understanding derives from in vitro assays, animal models, and published research on each component. Findings should be interpreted within their experimental context and not treated as established outcomes for any use supplied by Puritide Research. The blend is supplied strictly for laboratory use and is not approved for human or veterinary application.
Puritide Research supplies Tesamorelin + Ipamorelin Blend strictly for laboratory research use. Not for human or veterinary use.
Research Use Only
